1. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.
- Author
-
ROSA, KRISTI
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *RENAL cell carcinoma , *DRUG efficacy , *PATIENT aftercare , *COMBINATION drug therapy , *COLLEGE teacher attitudes , *TREATMENT effectiveness , *BENZAMIDE , *PROGRESSION-free survival , *OVERALL survival , *THERAPEUTICS - Abstract
The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.
- Published
- 2023